These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 26457416

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
    Fong DS, Custis P, Howes J, Hsu JW.
    Ophthalmology; 2010 Feb; 117(2):298-302. PubMed ID: 19969368
    [Abstract] [Full Text] [Related]

  • 23. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
    Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
    [Abstract] [Full Text] [Related]

  • 24. Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?
    Do DV.
    Ophthalmology; 2013 May; 120(5 Suppl):S8-10. PubMed ID: 23642785
    [Abstract] [Full Text] [Related]

  • 25. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
    Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S, MANTA Research Group.
    Br J Ophthalmol; 2013 Mar; 97(3):266-71. PubMed ID: 23292928
    [Abstract] [Full Text] [Related]

  • 26. Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load.
    Geirsdottir A, Jonsson O, Thorisdottir S, Helgadottir G, Jonasson F, Stefansson E, Sigurdsson H.
    Br J Ophthalmol; 2012 Mar; 96(3):444-7. PubMed ID: 21856691
    [Abstract] [Full Text] [Related]

  • 27. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
    Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, Henschien H, Fossen K, Markovic S, Pedersen TR, Sandvik L, Bragadóttir R.
    Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842
    [Abstract] [Full Text] [Related]

  • 28. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: a retrospective study of 58 patients.
    De Bats F, Grange JD, Cornut PL, Feldman A, Burillon C, Denis P, Kodjikian L.
    J Fr Ophtalmol; 2012 Nov; 35(9):661-6. PubMed ID: 23040443
    [Abstract] [Full Text] [Related]

  • 29. Bevacizumab for the treatment of neovascular age-related macular degeneration.
    Pitlick JM, Vecera KF, Barnes KN, Reski JW, Forinash AB.
    Ann Pharmacother; 2012 Feb; 46(2):290-6. PubMed ID: 22274144
    [Abstract] [Full Text] [Related]

  • 30. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
    Coleman AL, Yu F.
    Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
    [Abstract] [Full Text] [Related]

  • 31. Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life.
    Schmid MK, Reich O, Faes L, Boehni SC, Bittner M, Howell JP, Thiel MA, Signorell A, Bachmann LM.
    PLoS One; 2015 Jan; 10(8):e0135050. PubMed ID: 26241852
    [Abstract] [Full Text] [Related]

  • 32. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H, Shah CP, Weber M, Heier JS.
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [Abstract] [Full Text] [Related]

  • 33. Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab.
    Jiang S, Park C, Barner JC.
    J Clin Pharm Ther; 2014 Jun; 39(3):234-9. PubMed ID: 24635444
    [Abstract] [Full Text] [Related]

  • 34. Ranibizumab for age-related macular degeneration.
    Dhoot DS, Kaiser PK.
    Expert Opin Biol Ther; 2012 Mar; 12(3):371-81. PubMed ID: 22309606
    [Abstract] [Full Text] [Related]

  • 35. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
    Berg K, Pedersen TR, Sandvik L, Bragadóttir R.
    Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
    [Abstract] [Full Text] [Related]

  • 36. Patient-Centered Economic Burden of Exudative Age-Related Macular Degeneration: Retrospective Cohort Study.
    Choi K, Park SJ, Han S, Mun Y, Lee DY, Chang DJ, Kim S, Yoo S, Woo SJ, Park KH, Suh HS.
    JMIR Public Health Surveill; 2023 Dec 08; 9():e49852. PubMed ID: 38064251
    [Abstract] [Full Text] [Related]

  • 37. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F.
    Klin Oczna; 2010 Dec 08; 112(7-9):213-6. PubMed ID: 21121123
    [Abstract] [Full Text] [Related]

  • 38. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group.
    Ophthalmology; 2013 Nov 08; 120(11):2300-9. PubMed ID: 23916488
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity.
    Bandello F, Lafuma A, Berdeaux G.
    Invest Ophthalmol Vis Sci; 2007 Jan 08; 48(1):96-103. PubMed ID: 17197522
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.